(R)-tert-Butyl 2-(dimethylcarbamoyl)piperazine-1-carboxylate hydrochloride

Catalog No. :
ACPEUB103
CAS No. :
1217825-46-1
Molecular Formula :
C12H24ClN3O3
Molecular Weight :
293.80

IUPAC Name:tert-butyl (R)-2-(dimethylcarbamoyl)piperazine-1-carboxylate hydrochloride

(R)-tert-Butyl 2-(dimethylcarbamoyl)piperazine-1-carboxylate hydrochloride structure diagram
Pack SizePurityList PriceYour PriceGlobal StockUS StockQuantity
100mg95%$128.00Login to see priceInquiryInquiry
250mg95%$252.00Login to see priceInquiryInquiry
1g95%$509.00Login to see priceInquiryInquiry

Products of AiFChem are all designed for scientific research only. Under no circumstances do we provide products or services for animal or personal utilization.

Product Information

Product Name(R)-tert-Butyl 2-(dimethylcarbamoyl)piperazine-1-carboxylate hydrochloride
IUPAC Nametert-butyl (R)-2-(dimethylcarbamoyl)piperazine-1-carboxylate hydrochloride
MDL No.MFCD11112292
Molecular FormulaC12H24ClN3O3
Molecular Weight293.80
SMILESO=C(N1[C@@H](C(N(C)C)=O)CNCC1)OC(C)(C)C.[H]Cl
InChI KeyLBCLBCRUJZYOOS-SBSPUUFOSA-N
Synonym(R) 1-Boc-2-(diMethylcarbaMoyl)piperazine-HCl;(R)-tert-Butyl 2-(diMethylcarbaMoyl)piperazine-1-carboxylate hydrochloride;piperazine-1-carboxylate hydrochloride;-tert-Butyl 2-(dimethylcarbamoyl);Tert-butyl (R)-2-(dimethylcarbamoyl)piperazine-1-carboxylate hydrochloride
CAS No.1217825-46-1
PubChem CID45072790

Safety Data

Pictogram
Harmful or irritant
Signal Word
Achtung
Hazard Statement(s)
H302-H315-H319-H335
Precautionary Statement(s)
P261-P305+P351+P338

Synthetic Route by SureRoute

1. ACPEUB103 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Then
  3. ACPEUB103 route product structure diagram
    ACPEUB1031217825-46-1
Inquiry

2. ACPEUB103 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Then
  3. ACPEUB103 route product structure diagram
    ACPEUB1031217825-46-1
Inquiry

Comments (0)